Piper Jaffray Companies reaffirmed their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report issued on Friday morning. The brokerage currently has a $182.00 price target on the biopharmaceutical company’s stock.
ALNY has been the subject of a number of other reports. BidaskClub raised shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, August 5th. JMP Securities increased their target price on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an outperform rating in a research note on Wednesday, September 20th. Barclays PLC increased their target price on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a research note on Wednesday, November 8th. FBR & Co began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, October 30th. They set a buy rating and a $150.00 target price for the company. Finally, Cowen and Company reissued an outperform rating and set a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $121.85.
Shares of Alnylam Pharmaceuticals (ALNY) opened at $127.51 on Friday. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue was up 24.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.21) earnings per share. sell-side analysts expect that Alnylam Pharmaceuticals will post -5.33 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at Piper Jaffray Companies” was published by Week Herald and is the property of of Week Herald. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://weekherald.com/2017/11/20/alnylam-pharmaceuticals-alny-buy-rating-reiterated-at-piper-jaffray-companies.html.
In related news, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 289,797 shares of company stock worth $34,422,712. 4.30% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fayerweather Charles bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $230,000. Watch Point Trust Co bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Segall Bryant & Hamill LLC bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Security National Bank of SO Dak bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. Finally, Boston Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. 86.04% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.